For instance, an international registry of autoimmune diseases induced by biologics (the BIOGEAS registry) demonstrated that 0.33% of the patients exposed to biologics (97% of them were TNF-α inhibitors) developed DIL, and the frequency of DIL was higher in patients with RA (0.5%) and those treated with infliximab (0.66% vs. 0.49% for etanercept and 0.11% for adalimumab) [3]. Here, TNF is linked to autoimmune disease.